

RESEARCH

Open Access



Molecular characteristics of global β -lactamase-producing *Enterobacter cloacae* by genomic analysis

Jincao Hu^{1†}, Jia Li^{1†}, Chang Liu¹, Yan Zhang¹, Hui Xie¹, Chuchu Li², Han Shen^{1*} and Xiaoli Cao^{1*}

Abstract

Objective: To analyze the characteristics of global β -lactamase-producing *Enterobacter cloacae* including the distribution of β -lactamase, sequence types (STs) as well as plasmid replicons.

Methods: All the genomes of the *E. cloacae* were downloaded from GenBank. The distribution of β -lactamase encoding genes were investigated by genome annotation after the genome quality was checked. The STs of these strains were analyzed by multi-locus sequence typing (MLST). The distribution of plasmid replicons was further explored by submitting these genomes to the genome epidemiology center. The isolation information of these strains was extracted by Per program from GenBank.

Results: A total of 272 out of 276 strains were found to carry β -lactamase encoding genes. Among them, 23 varieties of β -lactamase were identified, bla_{CMH} ($n = 130$, 47.8%) and bla_{ACT} ($n = 126$, 46.3%) were the most predominant ones, 9 genotypes of carbapenem-hydrolyzing β -lactamase (CH β LS) were identified with bla_{VIM} ($n = 29$, 10.7%) and bla_{KPC} ($n = 24$, 8.9%) being the most dominant ones. In addition, 115 distinct STs for the 272 β -lactamase-carrying *E. cloacae* and 48 different STs for 106 CH β LS-producing *E. cloacae* were detected. ST873 ($n = 27$, 9.9%) was the most common ST. Furthermore, 25 different plasmid replicons were identified, IncHI2 ($n = 65$, 23.9%), IncHI2A ($n = 64$, 23.5%) and IncFII ($n = 62$, 22.8%) were the most common ones. Notably, the distribution of plasmid replicons IncHI2 and IncHI2A among CH β LS-producing strains were significantly higher than that among non-CH β LS-producing strains ($p < 0.05$).

Conclusion: Almost all the *E. cloacae* contained β -lactamase encoding gene. Among the global *E. cloacae*, bla_{CMH} and bla_{ACT} were main bla_{AmpC} genes. Bla_{TEM} and bla_{CTX-M} were the predominant ESBLs. Bla_{KPC} , bla_{VIM} and bla_{NDM} were the major CH β LS. Additionally, diversely distinct STs and different replicons were identified.

Keywords: *Enterobacter cloacae*, β -lactamase, Sequence type, Carbapenem-hydrolyzing β -lactamase

Introduction

Enterobacter (E. cloacae) belongs to facultative anaerobic Gram-negative bacilli, grouping into the *E. cloacae* complex group, the family *Enterobacteriaceae* [1]. Generally, such bacteria colonize soil and water as well as the animal and human gut, representing one of the most leading species described in clinical infections, particularly in vulnerable patients [2]. It has been reported that *E. cloacae* is frequently associated with a multidrug resistance (MDR) phenotype, due to the inducible overproducing

[†]Jincao Hu and Jia Li contributed equally to this work.

*Correspondence: shenhan10366@sina.com; cao-xiao-li@163.com

¹ Department of Laboratory Medicine, Nanjing Drum Tower Hospital, the Affiliated Hospital of Nanjing University Medical School, Zhongshan Road 321, GulouJiangsu Province, Nanjing, People's Republic of China
Full list of author information is available at the end of the article



AmpC β -lactamases and acquisition of numerous genetic mobile elements containing resistance [3]. More worrisome, the production of carbapenem-hydrolyzing β -lactamase (CH β LS) rendering ineffective almost all β -lactams families have been continually acquired, resulting in the production of super-resistant bacteria carbapenem-resistant *Enterobacter cloacae* (CREL) [4].

β -lactamase is a predominant resistance determinant for β -lactam antibiotics in *E. cloacae*. To date, there are two classification schemes for β -lactamases, the more groupings in clinical laboratory generally correlate with broadly based molecular classification, where β -lactamases are divided into class A, B, C and D enzymes based on the amino acid sequence [5]. Currently, the most problematic enzymes are plasmid-mediated AmpC β -lactamases (pAmpCs) with *bla*_{ACT-like} *ampC* genes being highly prevalent [6], extended-spectrum β -lactamases (ESBLs) with *bla*_{SHV} and *bla*_{CTX-M} being widely distributed [7], and CH β LS, all of which are challenging antibiotic effectiveness.

Globally, *bla*_{CH β LS} such as *bla*_{KPC} (class A), *bla*_{NDM/VIM/IMP} (class B) and *bla*_{OXA-48} (class D) are of grave clinical concern and proliferating [8]. It was reported that *bla*_{NDM-1} and *bla*_{NDM-5} were the main *bla*_{CH β LS}, ST93, ST171 and ST145 was the predominant sequence types (STs) for CREL in a tertiary Hospital in Northeast China during 2010–2019 [9]. Whereas in Japan, *bla*_{IMP-1} was the dominant *bla*_{CH β LS} conferring carbapenem resistance [10], and *bla*_{VIM} was the main *bla*_{CH β LS} in France between 2015–2018 [11]. However, the whole distribution of β -lactamase among global *E. cloacae* is unclear, and information on the clones of *E. cloacae* spreading internationally remains unknown. As we know that plasmids play an important role in horizontal gene transfer of antimicrobial resistance genes (ARG), and the identification of replicon types is helpful to analyze plasmid characteristics. Further, the association between plasmid replicons and different resistant determinants is essential to understand the role of plasmids in transmission of ARG [12]. For instance, IncN plasmids have been reported to be the predominant replicon types for *bla*_{IMP-4}-carrying strains [13], however, the prevalence of plasmid replicons among these bacteria were unknown. Notably, the association between IncIy plasmid encoding *bla*_{CMY-2} β -lactamase and the international ST19 was observed in multidrug-resistant *Salmonella Typhimurium* [14]. Whether or not this phenomenon could be observed in *E. cloacae* needs to be confirmed.

With the extensive use and development of antibacterial drugs, β -lactamases have evolved rapidly. Meanwhile, due to the rapid development of whole-genome sequencing (WGS) technology, the number of sequenced bacterial genomes has grown enormously, new β -lactamase

variants continue to be described. As a common opportunistic pathogen [15], the information on the distribution of β -lactamase among *E. cloacae* was limited.

In this study, we first explored the distribution of β -lactamase including pAmpCs, *bla*_{ESBLs} and *bla*_{CH β LS} among *E. cloacae* isolates based on a global database. For β -lactamase positive strains, the sequence types (STs) and the distribution of plasmid replicons were further investigated. Furthermore, the prevalent characteristics of β -lactamase-producing *E. cloacae* were analyzed.

Materials and methods

Acquisition of *E. cloacae* genomes and strain information

A total of 296 *E. cloacae* genomes were downloaded in batches from NCBI using Aspera software on 16th, Dec 2021 [16]. The genomic quality of these 296 strains was further filtered by Checkm and Quast software [17, 18]. The high-quality genome was defined as “completeness > 90% and containment < 5%”. Meanwhile, the quantity of contigs is required to be “ ≤ 500 , and N50 $\geq 40,000$ ”. Twenty genomes that did not meet the above conditions were filtered out. The investigated strains were collected from different years shown in Figure S1A, the collected dates of 58 strains were “blank” meaning that the information was missing. These strains were submitted by 32 countries, mainly from USA ($n=58$), France ($n=30$), United Kingdom ($n=27$), China ($n=24$), Japan ($n=18$), Singapore ($n=13$) and Nigeria ($n=12$), other countries were also involved (Figure S1B). The countries of 26 strains remained unknown. Notably, 158 out of 272 strains were hosted by Homo sapiens ($n=158$, 58.1%), mainly from gastrointestinal tract ($n=57$, 21.0%).

Investigation of β -lactamase among global *E. cloacae*

To avoid differences in genome gene prediction by different annotation methods. All the 276 genomes were annotated by Prokka software [19], which is a fast prokaryotic genome annotation software. All the strains containing β -lactamase encoding genes were further analyzed.

Analysis on the sequence type of β -lactamase carrying *E. cloacae*

The self-made Perl program was used to extract the nucleotide coding sequence of genes from each genome sequence file (GBK format) [20]. The allele sequences and allelic profiles of 7 conserved genes of *E. cloacae* were downloaded from website <https://pubmlst.org/>. The sequence of the genome was set as “query”, the seven conserved gene sequence files were set as “subject” (database). Blastn alignment analysis was then implemented between query and subject. The thresholds set were as follows: E-value = 1e-5, identity = 100%, matching length = subject gene length.

Investigation of plasmid replicons among β -lactamase positive *E. cloacae*

To analyze the distribution of plasmid replicons among β -lactamase-carrying *E. cloacae*. The genomes were submitted into the website and PlasmidFinder (<https://cge.cbs.dtu.dk/services/PlasmidFinder/>) was used to analyze the presence of plasmid replicons (Identity: 90%; Coverage: 90%).

Statistical analysis

The differences on the distribution of major resistant determinants and plasmid replicons among *bla*_{CH β LS}-carrying strains and strains without *bla*_{CH β LS} was analyzed by Chi-square test. Distribution difference on resistant determinants and plasmid replicons among all the β -lactamase-producing and among the *bla*_{CH β LS}-carrying strains were checked by McNemar test. The distribution rates were statistically different when *p* value was less than 0.05.

Results


The distribution of β -lactamase among global *E. cloacae*


In total, 272 out of 276 strains were found to carry β -lactamase encoding genes. There were 23 varieties of β -lactamase being found, *bla*_{CMH} (*n* = 130,

47.8%) and *bla*_{ACT} (*n* = 126, 46.3%) were the most predominant ones. Other β -lactamase encoding genes included *bla*_{TEM} (*n* = 90, 33.1%), *bla*_{OXA} (*n* = 51, 18.8%), *bla*_{CTX-M} (*n* = 48, 17.6%), *bla*_{VIM} (*n* = 29, 10.7%), *bla*_{KPC} (*n* = 24, 8.8%), *bla*_{SHV} (*n* = 23, 8.5%), *bla*_{NDM} (*n* = 22, 8.1%), *bla*_{IMI} (*n* = 17, 6.3%), *bla*_{MIR} (*n* = 11, 4.0%), *bla*_{LAP-2} (*n* = 10, 3.7%), *bla*_{IMP} (*n* = 7, 2.6%), *bla*_{DHA} (*n* = 7, 2.6%), *bla*_{GES} (*n* = 4, 1.5%), *bla*_{CMY} (*n* = 3, 1.1%), *bla*_{FOX-5} (*n* = 3, 1.1%), *bla*_{VEB-3} (*n* = 2, 0.7%), *bla*_{NMC-A} (*n* = 2, 0.7%), *bla*_{CARB} (*n* = 2, 0.7%), *bla*_{FLC-1} (*n* = 1, 0.4%), *bla*_{ORN-1} (*n* = 1, 0.4%) and *bla*_{SCO-1} (*n* = 1, 0.4%).

In detail, the variants of pAmpCs including *bla*_{CMH}, *bla*_{ACT} and *bla*_{MIR} were shown in Fig. 1, with *bla*_{CMH-6} (*n* = 41, 15.1%) and *bla*_{ACT-59} (*n* = 34, 12.5%) being the most frequent ones. Multiple variants of *bla*_{ESBLs} including *bla*_{CTX}, *bla*_{TEM}, *bla*_{OXA} and *bla*_{SHV} were also found (Fig. 2). Among them, *bla*_{CTX-M-15} (*n* = 33, 12.1%) and *bla*_{SHV-12} (*n* = 19, 7.0%) were the most common ones.

Overall, 9 genotypes of *bla*_{CH β LS} including *bla*_{NDM}, *bla*_{IMP}, *bla*_{OXA}, *bla*_{KPC}, *bla*_{VIM}, *bla*_{FLC-1}, *bla*_{NMC-A}, *bla*_{GES} and *bla*_{IMI} were found among 106 strains (Fig. 3). Besides the *bla*_{CH β LS} in the Fig. 3, other ones including *bla*_{OXA-48} (*n* = 3, 2.9%) and *bla*_{OXA-181} (*n* = 2, 1.9%), *bla*_{NMC-A} (*n* = 2, 1.9%) and *bla*_{FLC-1} (*n* = 1, 1.0%) were also identified.





The distribution of bla_{ACT} , bla_{SHV} and bla_{TEM} were obviously higher among bla_{CHBLs} -carrying *E. cloacae* comparing to the prevalence of these genes among the strains without bla_{CHBLs} ($p < 0.05$), whereas bla_{CMH} and oxacillin-hydrolyzing- bla_{OXA} were much more prevalent among *E. cloacae* strains without bla_{CHBLs} than bla_{CHBLs} -carrying ones ($p < 0.05$) (Table 1).

The sequence types of β -lactamase-carrying *E. cloacae*

Totally, there were 115 distinct STs for the 272 β -lactamase-carrying *E. cloacae* (Fig. 4). ST873 ($n = 27$, 23.5%) was the most frequent one followed by ST456 ($n = 11$, 9.6%). ST1 ($n = 9$, 7.8%), ST93 ($n = 5$, 4.3%) and ST976 ($n = 5$, 4.3%) were less common. The STs of 41 strains remained unknown and 12 strains belonged to novel STs. Other 110 STs were scattered (Fig. 4).

Furthermore, 48 different STs were identified for bla_{CHBLs} -carrying *E. cloacae* (Fig. 5). And ST873 ($n = 27$, 25.7%) and ST456 ($n = 11$, 10.5%) was the most common ones. Diverse STs were identified for bla_{CHBLs} -carrying *E. cloacae* (Fig. 6). Interestingly, all the 23 bla_{VIM-4} -carrying *E. cloacae*, and 3 out of 6 bla_{VIM-1} -carrying *E. cloacae*

isolates were assigned into ST873 (Fig. 6A). Whereas 19 bla_{KPC-2} ones were assigned to 13 STs (Fig. 6B), and 17 bla_{NDM-1} ones were assigned into 14 STs (Fig. 6C). Furthermore, 9 distinct STs for 17 bla_{IMP} -carrying strains (Fig. 6D), 7 different STs for 7 bla_{IMP} -carrying ones (Fig. 6E) and 2 STs for 5 strains carrying carbapenem-hydrolyzing bla_{OXA} (Fig. 6F) were identified. Of note, 27 out of 34 bla_{ACT-59} were found to be carried by ST873 strains.

The plasmid replicons of $CHBLs$ -carrying *E. cloacae*

Totally, 25 different plasmid replicons were identified. IncHI2 ($n = 65$, 23.9%), IncHI2A ($n = 64$, 23.5%) and IncFII ($n = 62$, 22.8%) were the most common ones followed by IncCol ($n = 48$, 17.6%), IncFII ($n = 41$, 15.1%) and IncR ($n = 28$, 10.3%). IncFIA ($n = 20$, 7.4%), IncN ($n = 18$, 6.6%), IncX3 ($n = 12$, 4.4%), IncC ($n = 8$, 2.9%), IncHI1B ($n = 8$, 2.9%), IncM1 ($n = 7$, 2.6%), IIncHI1A ($n = 6$, 2.2%), IncP6 ($n = 5$, 1.8%), pKPC-CAV1193 ($n = 4$, 1.5%), IncQ1 ($n = 3$, 1.1%), IncL ($n = 3$, 1.1%), IncX5 ($n = 2$, 0.7%), IncX4 ($n = 1$, 0.4%), IncM2 ($n = 1$, 0.4%), IncN2 ($n = 1$, 0.4%), IncP1 ($n = 1$, 0.4%), IncA




Table 1 The differences on the distribution of resistant determinants among *bla*_{CHBLs} positive and *bla*_{CHBLs} negative *Enterobacter cloacae*

	<i>bla</i> _{CHBLs} positive strains (n = 106)	<i>bla</i> _{CHBLs} negative strains (n = 166)	Chi-square value	P value
<i>bla</i> _{CMH} (n = 130)	41 (38.7%)	89 (53.6%)	5.873	0.016
<i>bla</i> _{ACT} (n = 126)	60 (56.7%)	66 (39.8%)	7.382	0.007
<i>bla</i> _{OXA} (n = 51)	3 (2.8%)	27 (16.3%)	10.569 ^a	0.001
<i>bla</i> _{CTX-M} (n = 48)	18 (17.0%)	29 (17.5%)	0.011	0.917
<i>bla</i> _{SHV} (n = 23)	16 (15.1%)	5 (3.0%)	13.255	0.000
<i>bla</i> _{TEM} (n = 90)	61 (57.5%)	29 (17.5%)	46.932	0.000

CHBLs Carbapenem-hydrolyzing β-lactamase


^a Continuity correction

(n = 1, 0.4%), repA (n = 1, 0.4%) and repB (n = 1, 0.4%) were also found. It was worth mentioning that no plasmid replicons were found among 97 strains, 62 (22.8%) out of which only contained one *bla*_{CMH}, 21 (7.7%) ones carried *bla*_{CHBLs}.

Notably, the prevalence of replicons IncHI2 and IncHI2A among *bla*_{CHBLs}-carrying strains were significantly higher than that among the strains without *bla*_{CHBLs} (p < 0.05), whereas no significant difference on the prevalence of plasmid replicons IncCOI, IncFII,

IncFIB and IncR among these two groups were observed (Table 2).

The distribution of *bla*_{SHV} was consistent with plasmid replicon IncR, and prevalence of *bla*_{CTX-M} was in accordance with the prevalence of IncFII, IncFIB and IncHI2A (p > 0.05). Additionally, the prevalence of oxacillin-hydrolyzing-*bla*_{OXA} and IncFIB as well as IncCOI was accordant (Table 3). Moreover, the prevalence of *bla*_{KPC} and *bla*_{VIM} were consistent with the distribution of IncCOI, IncFII, IncFIB, IncHI2 and IncHI2A, and no differences



were observed on the distribution of $bla_{IM\beta}$, bla_{NDM} and those of IncCOI, IncFII and IncFIB ($p > 0.05$) (Table 4).



Discussion

β -lactamase is a primary resistance determinant, widely disseminating on mobile genetic elements across the opportunistic pathogens including *E. cloacae* [21]. Exploring the spread characteristics of β -lactamase among *E. cloacae* based on the global genome database of GenBank is quite important for illustrating the resistance characteristics of such strains and guiding rational drug use in clinic.

Our analysis showed that the number of *E. cloacae* has been continuously increasing since the genome of first one was submitted in 2003. More than 32 countries all over the world submitted the genomes, indicating the representativeness of these strains. To note, the host of these β -carrying *E. cloacae* strains were predominantly Homo sapiens, with the gastrointestinal tract being the

major isolation resource, suggesting that Homo sapiens were the dominant host and gastrointestinal tract was predilection seat. Importantly, 106 $bla_{CH\beta LS}$ -carrying *E. cloacae* strains isolated during 2010–2020 were scattered among global 27 countries and 5 continents, indicating a rapid emergence and wide distribution of such strain, which alerts us the urgency of implementation of prevention and control measures.

Our analysis showed that bla_{CMH} was the most frequent β -lactamase gene. However, literature search with bla_{CMH} as the key word showed that bla_{CMH-1} was first detected in *E. cloacae* as a novel bla_{AmpC} gene at a Medical Center in Southern Taiwan [22]. Since then, bla_{CMH-2} and bla_{CMH-3} were sequentially identified in India and Europe [22, 23]. Thereafter, no bla_{CMH} was reported in PubMed database albeit genomic analysis showed the widest distribution of these enzyme. To our surprise, the most prevalent bla_{CMH-6} , bla_{CMH-4} , bla_{CMH-5} and bla_{CMH-3} were not identified among *E. cloacae* at all. Moreover, bla_{ORN-1} ,



identified in the chromosome of *Raoultella ornithinolytica* in 2004 [24, 25], has never been reported in *E. cloacae*. Interestingly, *bla*_{CARB-2} as a carbenicillin-hydrolyzing enzyme, has been identified within multiple strains

including *Klebsiella pneumonia* [26], *Achromobacter xylosoxidans* [27], *Escherichia coli* [28], *Acinetobacter pittii* [29] and *E. cloacae* [30] in a variety of countries, however, was quite rare in our study. Which may be related

Table 2 The differences on the distribution of plasmid replicons among *bla*_{CHβLs} positive and *bla*_{CHβLs} negative *Enterobacter cloacae*

	<i>bla</i> _{CHβLs} positive strains (n = 106)	<i>bla</i> _{CHβLs} negative strains (n = 166)	Chi-square	P value
IncCOI (n = 41)	21 (19.8%)	20 (12.4%)	3.046	0.081
IncFII (n = 62)	28 (26.4%)	34 (37.3%)	1.294	0.255
IncFIB (n = 58)	29 (27.4%)	29 (17.5%)	3.771	0.052
IncHI2 (n = 65)	37 (34.9%)	28 (16.9%)	11.574	0.001
IncHI2A (n = 64)	37 (57.5%)	27 (16.3%)	12.493	0.000
IncR (n = 27)	9 (8.5%)	19 (11.4%)	0.612	0.434

CHβLs Carbapenem-hydrolyzing β-lactamase

to its clinical importance. *bla*_{LAP-2} as a narrow-spectrum β-lactamase was also rare in our study, albeit it has been reported [31] [32]. Furthermore, *bla*_{SCO-1} was a novel plasmid-mediated class A β-lactamase with carbenicillinase characteristics in *E. coli* [33], has not been reported in *E. cloacae* until now. As we know that *bla*_{ACT} was also a plasmid-encoded *ampC* gene [34]. Although the prevalence of *bla*_{ACT} was secondary to *bla*_{CMH} in our study, distribution of exact *bla*_{ACT}-variants was not so high. Note worthily, the most common *bla*_{ACT-59} in our study has never been reported. Which may be due to the limitation of screening methods. It was reported that *bla*_{VEB-3} was encoded by the chromosome and located in an integron, and only 2 *bla*_{VEB-2} genes were detected in our study.

However, outbreak of infection caused by *bla*_{VEB-3}-carrying-*E. cloacae* has been reported in China [35],

Additionally, *bla*_{KPC}, *bla*_{VIM}, *bla*_{NDM}, *bla*_{IMI} and *bla*_{IMP} were the major *bla*_{CHβLs} accounting for carbapenem resistance in global *E. cloacae*. Among them, *bla*_{KPC-2} and *bla*_{VIM-4} were the most predominant ones. Which is a light different from previous report showing *bla*_{KPC-2} and *bla*_{IMP-8} was the main *bla*_{CHβLs} within *E. cloacae* in China [36]. Noteworthily, 28 *bla*_{VIM-4}-carrying *E. cloacae* ST873 were only found in Homo sapiens in France, indicating that there was a clonal dissemination of such strain among Homo sapiens in France during 2010–2020, which was not reported previously, albeit nosocomial infections caused by *E. cloacae* ST873 in 2 hospitals in France has been reported [37]. As a novel *bla*_{CHβLs}, *bla*_{FLC-1} belongs to Ambler class A β-lactamases, has been identified an *E. cloacae* Complex isolated from food products [38]. Interestingly, such enzyme displayed a distinctive substrate profile, hydrolyzing penicillin, narrow- and broad-spectrum cephalosporins, aztreonam, and carbapenems but not extended-spectrum cephalosporin. In addition, *bla*_{NMC-A}, a class A *bla*_{CHβL}, has been frequently detected in *E. cloacae* [39, 40] [41, 42], albeit we just found 2 *bla*_{NMC-A} in this study. As *bla*_{CHβLs}, *bla*_{GES-24} seems to have a broader host than *bla*_{GES-2} although we only found 2 *bla*_{GES-2} and 1 *bla*_{GES-24} in this study. To date, all reports on *bla*_{IMI-1} focus on *E. cloacae*, indicating that *E. cloacae* may be the best host for *bla*_{IMI}.

Table 3 The differences on the distribution of plasmid replicons and resistant determinants among the β-lactamase producing *Enterobacter cloacae*

	<i>bla</i> _{CMH} (n = 130)	<i>bla</i> _{ACT} (n = 126)	<i>bla</i> _{OXA} ^a (n = 43)	<i>bla</i> _{CTM-M} (n = 47)	<i>bla</i> _{SHV} (n = 21)	<i>bla</i> _{TEM} (n = 90)
IncCOI (n = 48)	0.000	0.000	0.609	1.000	0.000	0.000
IncFII (n = 62)	0.000	0.000	0.037	0.137	0.000	0.012
IncFIB (n = 58)	0.000	0.000	0.146	0.272	0.000	0.041
IncHI2 (n = 65)	0.000	0.000	0.023	0.038	0.000	0.005
IncHI2A (n = 64)	0.000	0.000	0.031	0.053	0.000	0.003
IncR (n = 28)	0.000	0.000	0.006	0.007	0.347	0.000

^a Oxacillin-hydrolyzing-OXA

Table 4 The differences on the distribution of plasmid replicons and resistant determinants among the *bla*_{CHβLs}-carrying *Enterobacter cloacae*

Plasmid replicons	<i>bla</i> _{KPC} (n = 24)	<i>bla</i> _{IMI} (n = 17)	<i>bla</i> _{VIM} (n = 29)	<i>bla</i> _{NDM} (n = 22)
IncCOI (n = 21)	0.736	0.627	0.268	1.000
IncFII (n = 28)	0.652	0.080	1.000	0.451
IncFIB (n = 29)	0.551	0.058	1.000	0.337
IncHI2 (n = 37)	0.085	0.008	0.200	0.036
IncHI2A (n = 37)	0.085	0.008	0.200	0.036

CHβLs Carbapenem-hydrolyzing β-lactamase

The higher prevalence of *bla*_{TEM} and *bla*_{SHV} among *bla*_{CHβLs}-carriers in our study was in accordance with a previous report to some degree, which showed that *bla*_{CTX-M}, *bla*_{TEM} and *bla*_{SHV} were mostly detected concurrently with *bla*_{CHβLs} [43]. Albeit no distribution difference of *bla*_{CTX-M} was observed. Notably, the significantly higher distribution of *bla*_{CMH} among non-CHβLs-producers may indicate that *bla*_{CMH} may be the predominant gene conferring β-lactams among the strains without *bla*_{CHβLs}.

Furthermore, the multiple STs identified in our study displayed a genetic diversity of β-lactamase producing *E. cloacae*. It seemed that clonal dissemination for such strain was rare except for *bla*_{VIM-4}-carrying ST873 ones, suggesting that the spread of CREL was mainly mediated by mobile elements such as plasmids.

Additionally, variously distinct plasmid replicons detected in our study indicate their dissemination potential for resistant determinants. Noteworthy, the obviously higher prevalence of IncHI2 and IncHI2A among *bla*_{CHβLs}-carrying strains may suggest association between *bla*_{CHβLs} and IncHI2. It was reported that IncHI2 widely detected in global CRE genomes, was termed as 'super-plasmids' resulting from the large size and prolific carriage of resistance determinants [44]. And the consistent distribution of such plasmid and *bla*_{KPC} and *bla*_{VIM} may indicate a good cost fitness between them.

There were several limitations in this study. First, the number of *E. cloacae* was relatively small which may result from the reason that *E. cloacae* was only little part of *E. cloacae* complex. Second, the resistance profiles of these strains were not available for us to compare the difference between the genotypes and phenotypes. Some of the strain information were missing, which was not beneficial for us to fully illustrate the characterization of *E. cloacae*. Third, some new enzymes are devoid of further phenotypic descriptions because they were directly obtained from whole-genome sequencing studies. Anyway, it is currently difficult to draw an accurate global picture of this bacteria, highlighting the need for more comprehensive genome sequence data and genomic analysis.

In summary, almost all the *E. cloacae* contained β-lactamase encoding gene. Among the global *E. cloacae*, *bla*_{CMH} and *bla*_{ACT} were main *bla*_{AmpC} genes. *Bla*_{TEM} and *bla*_{CTX-M} were the predominant ESBLs. *Bla*_{KPC}, *bla*_{VIM} and *bla*_{NDM} were the major CHβLs. Additionally, diversely distinct STs and different replicons were identified.

Abbreviations

CRE: Carbapenem-resistant Enterobacteriaceae; ESBLs: Extended-spectrum β-lactamases; CHβLs: Carbapenem-hydrolyzing β-lactamase; pAmpCs: Plasmid-mediated AmpC β-lactamases; CREL: Carbapenem resistance

Klebsiella pneumoniae; KPC: *Klebsiella pneumoniae* Carbapenemase; NDM: New Delhi metallo-beta-lactamase; ESBLs: Extended-spectrum β-lactamases; MLST: Multi-locus sequence typing; STs: Sequence types.

Supplementary Information

The online version contains supplementary material available at <https://doi.org/10.1186/s12866-022-02667-y>.

Additional file 1.

Acknowledgements

We are very grateful to Tianshe Li for providing technical help on data sorting and bioinformatic analysis.

Disclaimer

The views expressed in this article are those of the authors and do not necessarily reflect the official policy or position of the Department of Laboratory Medicine, Nanjing Drum Tower Hospital, the affiliated Hospital of Nanjing University Medical School, and the Clinical Research Center, the second hospital of Nanjing, Nanjing University of Chinese Medicine, Nanjing, 210,003, China.

Authors' contributions

HJC performed the Bioinformatics analysis and writing; LJ sorted the data and help with the writing; LC, LCC and ZY interpreted the data regarding the resistant determinants and plasmid replicons. XH performed statistical analysis. SH and CXL designed the work and were a major contributor in revising the manuscript. All authors read and approved the final manuscript.

Funding

This work was supported by the National Natural Science Foundation of China (81902124 and 82002205).

Availability of data and materials

The datasets used and/or analyzed during the current study are available from GenBank and the accession number and web link to datasets for the provided name of these strains were shown in table S1.xlsx.

Declarations

Ethics approval and consent to participate

Not applicable.

Consent for publication

Not applicable.

Competing interests

The authors declare that they have no competing interests.

Author details

¹Department of Laboratory Medicine, Nanjing Drum Tower Hospital, the Affiliated Hospital of Nanjing University Medical School, Zhongshan Road 321, GulouJiangsu Province, Nanjing, People's Republic of China. ²Department of Acute Infectious Disease Control and Prevention, Jiangsu Provincial Center for Disease Control and Prevention, Nanjing, China.

Received: 26 July 2022 Accepted: 10 October 2022

Published online: 21 October 2022

References

1. Wu W, Wei L, Feng Y, Xie Y, Zong Z. Precise species identification by whole-genome sequencing of enterobacter bloodstream infection. *China Emerg Infect Dis.* 2021;27(1):161–9.
2. Stokes W, Peirano G, Matsumara Y, Nobrega D, Pitout JDD. Population-based surveillance of *Enterobacter cloacae* complex causing blood

- stream infections in a centralized Canadian region. *Eur J Clin Microbiol Infect Dis*. 2022;41(1):119–25.
3. Ito A, Nishikawa T, Ota M, Ito-Horiyama T, Ishibashi N, Sato T, et al. Stability and low induction propensity of cefiderocol against chromosomal AmpC beta-lactamases of *Pseudomonas aeruginosa* and *Enterobacter cloacae*. *J Antimicrob Chemother*. 2018;73(11):3049–52.
 4. Davin Regli A, Lavigne JP, Pages JM. *Enterobacter* spp.: update on taxonomy, clinical aspects, and emerging antimicrobial resistance. *Clin Microbiol Rev*. 2019;32(4):e00002-19.
 5. Tooke CL, Hinchliffe P, Bragginton EC, Colenso CK, Hirvonen VHA, Takebayashi Y, et al. beta-Lactamases and beta-Lactamase Inhibitors in the 21st Century. *J Mol Biol*. 2019;431(18):3472–500.
 6. Peymani A, Naserpour-Farivar T, Yeylagh-Beygi M, Bolori S. Emergence of CMY-2- and DHA-1-type AmpC beta-lactamases in *Enterobacter cloacae* isolated from several hospitals of Qazvin and Tehran. *Iran Iran J Microbiol*. 2016;8(3):168–74.
 7. Garza-Gonzalez E, Bocanegra-Ibarias P, Bobadilla-Del-Valle M, Ponce-de-Leon-Garduno LA, Esteban-Kenel V, Silva-Sanchez J, et al. Drug resistance phenotypes and genotypes in Mexico in representative gram-negative species: Results from the infivar network. *PLoS ONE*. 2021;16(3):e0248614.
 8. Han R, Shi Q, Wu S, Yin D, Peng M, Dong D, et al. Dissemination of Carbapenemases (KPC, NDM, OXA-48, IMP, and VIM) among carbapenem-resistant enterobacteriaceae isolated from adult and children patients in China. *Front Cell Infect Microbiol*. 2020;10:314.
 9. Chen J, Tian S, Nian H, Wang R, Li F, Jiang N, et al. Carbapenem-resistant *Enterobacter cloacae* complex in a tertiary Hospital in Northeast China, 2010–2019. *BMC Infect Dis*. 2021;21(1):611.
 10. Kananizadeh P, Oshiro S, Watanabe S, Iwata S, Kuwahara-Arai K, Shimojima M, et al. Emergence of carbapenem-resistant and colistin-susceptible *Enterobacter cloacae* complex co-harboring blaIMP-1 and mcr-9 in Japan. *BMC Infect Dis*. 2020;20(1):282.
 11. Emeraud C, Petit C, Gauthier L, Bonnin RA, Naas T, Dortet L. Emergence of VIM-producing *Enterobacter cloacae* complex in France between 2015 and 2018. *J Antimicrob Chemother*. 2022;77(4):944–51.
 12. Rozwandowicz M, Brouwer MSM, Fischer J, Wagenaar JA, Gonzalez-Zorn B, Guerra B, et al. Plasmids carrying antimicrobial resistance genes in *Enterobacteriaceae*. *J Antimicrob Chemother*. 2018;73(5):1121–37.
 13. Liu W, Dong H, Yan T, Liu X, Cheng J, Liu C, et al. Molecular Characterization of blaIMP-4-Carrying *Enterobacteriales* in Henan Province of China. *Front Microbiol*. 2021;12:626160.
 14. Dong N, Li Y, Zhao J, Ma H, Wang J, Liang B, et al. The phenotypic and molecular characteristics of antimicrobial resistance of *Salmonella enterica* subsp. *enterica* serovar Typhimurium in Henan Province, China. *BMC Infect Dis*. 2020;20(1):511.
 15. Chen Q, Lin Y, Li Z, Lu L, Li P, Wang K, et al. Characterization of a new transposon, Tn6696, on a blaNDM-1-carrying plasmid from multidrug-resistant *enterobacter cloacae* ssp. *dissolvens* in China. *Front Microbiol*. 2020;11:525479.
 16. Kim T, Seo HD, Hennighausen L, Lee D, Kang K. Octopus-toolkit: a workflow to automate mining of public epigenomic and transcriptomic next-generation sequencing data. *Nucleic Acids Res*. 2018;46(9):e53.
 17. Khezri A, Avershina E, Ahmad R. Hybrid assembly provides improved resolution of plasmids, antimicrobial resistance genes, and virulence factors in *Escherichia coli* and *Klebsiella pneumoniae* clinical isolates. *Microorganisms*. 2021;9(12):2560.
 18. Cornet L, Meunier L, Van Vlierberghe M, Leonard RR, Durieu B, Lara Y, et al. Consensus assessment of the contamination level of publicly available cyanobacterial genomes. *PLoS ONE*. 2018;13(7):e0200323.
 19. Marchi E, Jones M, Klenerman P, Frater J, Magiorkinis G, Belshaw R. BreakAlign: a Perl program to align chimaeric (split) genomic NGS reads and allow visual confirmation of novel retroviral integrations. *BMC Bioinformatics*. 2022;23(1):134.
 20. Wang Q, Wang X, Wang J, Ouyang P, Jin C, Wang R, et al. Phenotypic and Genotypic Characterization of Carbapenem-resistant *Enterobacteriaceae*: Data From a Longitudinal Large-scale CRE Study in China (2012–2016). *Clin Infect Dis*. 2018;67(suppl_2):S196–205.
 21. Ku YH, Lee MF, Chuang YC, Yu WL. Detection of Plasmid-Mediated beta-Lactamase Genes and Emergence of a Novel AmpC (CMH-1) in *Enterobacter cloacae* at a Medical Center in Southern Taiwan. *J Clin Med*. 2018;8(1):8.
 22. Ingti B, Laskar MA, Choudhury S, Maurya AP, Paul D, Talukdar AD, et al. Molecular and in silico analysis of a new plasmid-mediated AmpC beta-lactamase (CMH-2) in clinical isolates of *Klebsiella pneumoniae*. *Infect Genet Evol*. 2017;48:34–9.
 23. López Hernández I, García Barrionuevo A, Díaz de Alba P, Clavijo E, Pascual A. Characterization of NDM-1- and CMH-3-producing *Enterobacter cloacae* complex ST932 in a patient transferred from Ukraine to Spain. *Enferm Infect Microbiol Clin (English ed)*. 2020;38(7):327–30.
 24. Bush K. Past and Present Perspectives on beta-Lactamases. *Antimicrob Agents Chemother*. 2018;62(10).
 25. Walckenaer E, Poirel L, Leflon-Guibout V, Nordmann P, Nicolas-Chanoine MH. Genetic and biochemical characterization of the chromosomal class A beta-lactamases of *Raoultella* (formerly *Klebsiella*) *planticola* and *Raoultella ornithinolytica*. *Antimicrob Agents Chemother*. 2004;48(1):305–12.
 26. Zhu LC, Lu JW, Wang J, Xu T, Xu JH. Analyses on distribution and structure of bla(CARB-2) in *Klebsiella pneumoniae*. *Yi Chuan*. 2018;40(7):593–600.
 27. Zhu Z, Xu J, He F. Genomic and phylogenetic analysis of multidrug-resistant *Achromobacter xylosoxidans* ST273 strain MTYH1 co-carrying blaOXA-114g and blaCARB-2 recovered from a wound infection in China. *J Glob Antimicrob Resist*. 2021;25:110–3.
 28. Atlaw NA, Keelara S, Correa M, Foster D, Gebreyes W, Aidara-Kane A, et al. Identification of CTX-M Type ESBL *E. coli* from sheep and their Abattoir environment using whole-genome sequencing. *Pathogens*. 2021;10(11):1480.
 29. Kamolvit W, Derrington P, Paterson DL, Sidjabat HE. A case of IMP-4-, OXA-421-, OXA-96-, and CARB-2-producing *Acinetobacter pittii* sequence type 119 in Australia. *J Clin Microbiol*. 2015;53(2):727–30.
 30. Rodriguez-Martinez JM, Nordmann P, Poirel L. Group IIC intron with an unusual target of integration in *Enterobacter cloacae*. *J Bacteriol*. 2012;194(1):150–60.
 31. Huang Z, Mi Z, Wang C. A novel beta-lactamase gene, LAP-2, produced by an *Enterobacter cloacae* clinical isolate in China. *J Hosp Infect*. 2008;70(1):95–6.
 32. Kocsis B, Kocsis E, Fontana R, Cornaglia G, Mazzariol A. Identification of blaLAP-2 and qnrS1 genes in the internationally successful *Klebsiella pneumoniae* ST147 clone. *J Med Microbiol*. 2013;62(Pt 2):269–73.
 33. Papagiannitsis CC, Loli A, Tzouveleki LS, Tzelepi E, Arlet G, Miriagou V. SCO-1, a novel plasmid-mediated class A beta-lactamase with carbapenemase characteristics from *Escherichia coli*. *Antimicrob Agents Chemother*. 2007;51(6):2185–8.
 34. Reisbig MD, Hossain A, Hanson ND. Factors influencing gene expression and resistance for Gram-negative organisms expressing plasmid-encoded ampC genes of *Enterobacter* origin. *J Antimicrob Chemother*. 2003;51(5):1141–51.
 35. Jiang X, Ni Y, Jiang Y, Yuan F, Han L, Li M, et al. Outbreak of infection caused by *Enterobacter cloacae* producing the novel VEB-3 beta-lactamase in China. *J Clin Microbiol*. 2005;43(2):826–31.
 36. Dai W, Sun S, Yang P, Huang S, Zhang X, Zhang L. Characterization of carbapenemases, extended spectrum beta-lactamases and molecular epidemiology of carbapenem-non-susceptible *Enterobacter cloacae* in a Chinese hospital in Chongqing. *Infect Genet Evol*. 2013;14:1–7.
 37. Beyrouthy R, Baretts M, Marion E, Dananché C, Dauwalder O, Robin F, et al. Novel *Enterobacter* Lineage as Leading Cause of Nosocomial Outbreak Involving Carbapenemase-Producing Strains. *Emerg Infect Dis*. 2018;24(8):1505–15.
 38. Brouwer MSM, Tehrani K, Rapallini M, Geurts Y, Kant A, Harders F, et al. Novel Carbapenemases FLC-1 and IMI-2 Encoded by an *Enterobacter cloacae* Complex Isolated from Food Products. *Antimicrob Agents Chemother*. 2019;63(6):e02338-18.
 39. Mariotte-Boyer S, Nicolas-Chanoine MH, Labia R. A kinetic study of NMC-A beta-lactamase, an Ambler class A carbapenemase also hydrolyzing cephamycins. *FEMS Microbiol Lett*. 1996;143(1):29–33.
 40. Swarén P, Maveyraud L, Raquet X, Cabantous S, Duez C, Pédelacq JD, et al. X-ray analysis of the NMC-A beta-lactamase at 1.64-Å resolution, a class A carbapenemase with broad substrate specificity. *J Biol Chem*. 1998;273(41):26714–21.
 41. Boyd DA, Mataseje LF, Davidson R, Delpoit JA, Fuller J, Hoang L, et al. *Enterobacter cloacae* Complex Isolates Harboring bla(NMC-A) or bla(IMI)-Type Class A Carbapenemase Genes on Novel Chromosomal Integrative Elements and Plasmids. *Antimicrob Agents Chemother*. 2017;61(5):e02578-16.

42. Antonelli A, D'Andrea MM, Di Pilato V, Viaggi B, Torricelli F, Rossolini GM. Characterization of a Novel Putative Xer-Dependent Integrative Mobile Element Carrying the bla(NMC-A) Carbapenemase Gene, Inserted into the Chromosome of Members of the *Enterobacter cloacae* Complex. *Antimicrob Agents Chemother*. 2015;59(10):6620–4.
43. Kopotsa K, Osei Sekyere J, Mbelle NM. Plasmid evolution in carbapenemase-producing Enterobacteriaceae: a review. *Ann NY Acad Sci*. 2019;1457(1):61–91.
44. Macesic N, Blakeway LV, Stewart JD, Hawkey J, Wyres KL, Judd LM, et al. Silent spread of mobile colistin resistance gene mcr-9.1 on IncHI2 “superplasmids” in clinical carbapenem-resistant Enterobacterales. *Clin Microbiol Infect*. 2021;27(12):1856.e7–e13.

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Ready to submit your research? Choose BMC and benefit from:

- fast, convenient online submission
- thorough peer review by experienced researchers in your field
- rapid publication on acceptance
- support for research data, including large and complex data types
- gold Open Access which fosters wider collaboration and increased citations
- maximum visibility for your research: over 100M website views per year

At BMC, research is always in progress.

Learn more biomedcentral.com/submissions

